Cross-study safety trends: when the same safety signal appears in multiple studies at your site
Analyze portfolio-level safety data for cross-study trends invisible within any single study, apply a structured signal detection framework with defined thresholds and analysis frequency, and evaluate the appropriate escalation path while maintaining the RC's coordination role.
The pattern no one else can see
Every principal investigator at a multi-study site sees one thing clearly: the safety profile of each study they supervise. The oncologist running a taxane trial knows the neuropathy rate in that protocol. The endocrinologist managing a GLP-1 agonist study knows the gastrointestinal event profile for that compound. The rheumatologist overseeing a TNF inhibitor trial knows the infection signals in that population. Each investigator is, appropriately, focused on the safety data within their own studies.
But none of them sees across studies. None of them has the vantage point to notice that peripheral neuropathy appeared in the oncology trial last month, the diabetes trial this month, and the rheumatology trial the month before that. Three different investigators, three different compounds, three different therapeutic areas -- and each one assessed the event as expected or unremarkable within the context of their individual protocol. No alarm sounded. No escalation occurred. No one connected the dots.
Except the regulatory coordinator.
The RC is the only person at the site whose daily work touches every active study's safety data. Not the clinical details -- that remains the investigator's domain. But the reporting flows, the event categories, the AE terms, the temporal patterns. The RC who manages safety reporting across 12 or 16 studies occupies a unique vantage point: the portfolio view. And from that vantage point, patterns invisible to any individual investigator become visible.
This lesson is about what to do with that visibility. Not how to make clinical judgments -- that is and will always remain the investigator's nondelegable responsibility. But how to recognize when the portfolio-level data suggests something worth examining, how to structure that recognition into a defensible process, and how to escalate appropriately when a cross-study trend demands attention.
ICH E6(R3), Principle 1, Section 1.2 states that the safety of participants should be reviewed in a timely manner as new safety information becomes available that could have an impact on participant safety, their willingness to continue in the trial, or the conduct of the trial. The cross-study trend is precisely the kind of "new safety information" this provision contemplates -- information that emerges not from a single study but from the aggregated view that only the portfolio-level coordinator possesses.
What you will learn
By the end of this lesson, you will be able to: